'My colon blew up': The shocking truth behind GLP-1 weight-loss drugs and their potential risks.
Imagine waking up one day and finding yourself suddenly blind, or experiencing a ruptured colon while driving your granddaughter home. These are the harrowing stories of three individuals who have filed lawsuits against the manufacturers of popular weight-loss drugs known as GLP-1 receptor agonists.
Todd Engel, a Maryland truck driver, shares his devastating experience with Ozempic. He woke up one morning with a loss of vision in one eye, and soon after, the other. Engel's diagnosis was non-arteritic anterior ischemic optic neuropathy (NAION), often referred to as an 'eye stroke.' Despite extensive testing, the cause remained a mystery, and his medication was not initially suspected. But research suggests a potential link between semaglutide, the active ingredient in Ozempic, and this eye condition.
But here's where it gets controversial...
European labels for Ozempic and Wegovy now state that semaglutide may cause NAION in up to 1 in 10,000 patients. However, U.S. labels only warn of vision changes without mentioning NAION specifically. Engel believes that if he and his doctors had been aware of this potential risk, he would have reconsidered taking the drug.
In another case, JoHelen McClain, a real estate agent from Oklahoma, started taking Wegovy with the simple goal of losing weight and feeling healthier. She achieved her weight loss goal, but at a terrible cost. While driving her granddaughter home, McClain's colon ruptured, and she had to undergo surgery to remove a large portion of it. She now lives with a stoma and a bag to collect stool, facing leaks, anxiety, and depression.
McClain's lawsuit alleges that Wegovy caused her colon to rupture and that the drug manufacturer did not adequately warn of these severe risks.
And this is the part most people miss...
Mark Smith's wife, Robin, experienced severe gastric problems and frequent vomiting after starting Mounjaro for weight loss. Despite stopping the drug, her gastric issues persisted, and she was eventually diagnosed with Wernicke's encephalopathy, a neurological condition caused by a vitamin B1 deficiency. Robin's condition has left her struggling to walk, suffering from confusion and memory loss, and unable to recognize her husband at times.
Smith's lawsuit alleges that Mounjaro caused gastroparesis, which led to the development of Wernicke's encephalopathy. Eli Lilly, the manufacturer of Mounjaro, has noted that the drug's labels have always warned of severe gastrointestinal reactions, but Robin's daughter believes the risks were not fully disclosed.
These lawsuits are part of a growing number of legal challenges against the makers of GLP-1 drugs, with over 4,400 patients filing suits. The plaintiffs argue that the drug warnings were insufficient and did not prepare them for the severe injuries they experienced. The legal battle raises important questions about drug risk warnings and public trust.
As the use of GLP-1 drugs skyrockets, with millions turning to them for diabetes management, weight loss, and other health benefits, it's crucial to consider the potential risks and ensure that patients are fully informed. While these drugs show promise in aiding various conditions, no medicine is without risk. It's a delicate balance, and the stories of Engel, McClain, and Smith serve as a stark reminder of the potential consequences.
What are your thoughts on these lawsuits and the potential risks associated with GLP-1 weight-loss drugs? Do you think the drug manufacturers should have provided more detailed warnings? Share your opinions in the comments below!
